Search Results

Tags C5aR1 , CXCR4 , G protein-coupled receptor (GPCR) , GPCR trafficking , Ncdn , Neurochondrin , P-Rex1

Thomas P. Sakmar About Dr. Thomas P. Thomas P.

higher in the case group as compared to the control group (positivity 40.31 ± 3.01 vs. 20.46 ± 1.93, p < 0.001; density 2.77 ± 1.17 vs. 1.28 ± 0.37, p < 0.001). mRNA level was also upregulated in patients compared to the controls (2.36 ± 1.30 vs. 1.09 ± 0.42, p < 0.001) and showed a positive correlation with immunostaining of protein in OSCC (r = 0.48, p = 0.011 differentiation (p = 0.013), clinical TNM stages (p = 0.014), and poor survival (p = 0.006) of patients

Low PAXIP1-AS1 expression in OC was associated with age (P = 0.045), histological grade (P = 0.011), and lymphatic invasion (P = 0.004). Low PAXIP1-AS1 expression predicted a poorer overall survival (OS) (HR: 0.71; 95% CI: 0.55-0.92; P = survival (DSS) (HR: 0.67; 95% CI: 0.51-0.89; P = 0.006). PAXIP1-AS1 expression (HR: 0.711; 95% CI: 0.542-0.934; P = 0.014) was independently correlated with PFS

β1 AR) , M5-muscarinic (M5AR), and angiotensin II type 2 receptors (AT2R) were increased in HF (all P against α1 -adrenergic (α1 AR) and angiotensin II type 1 receptors (AT1R) were decreased in HF (all P < 0.05) and global longitudinal strain (r = -0.323, P < 0.05). In insulin-resistant HF patients, AT2R autoantibodies were decreased (r = -.240, P < 0.05), and AT1R autoantibodies were increased (r = 0.212, P < 0.05).

to promote the expressions of GPRC5A compared with those of the NC group (1.00±0.01, 1.00±0.00)(all P< increase of GPRC5A at both gene and protein levels induced by LPS (1.30±0.10, 1.43±0.03) (F=208.38, P< 0.001; F=42.04, P<0.001). PTGS2 at the gene level in LPS group were highly increased compared with those in the NC group (all P< in the NC group, and siGPRC5A could effectively suppressed LPS-induced protein phosphorylation (all P<

significantly lower with CAR-T compared to BsAb at 1-year (incidence-rate-ratio [IRR] = 0.43, 95%CI 0.25-0.76, P treatment-emergent hypogammaglobulinemia, BsAb recipients had higher infection rates (IRR:2.27, 1.31-3.98, P = 0.004) and time to severe infection (HR 2.04, 1.05-3.96, P = 0.036) than their CAR-T counterparts. During periods of non-neutropenia, CAR-T recipients had a lower risk (HR 0.44, 95%CI 0.21-0.93, P = 0.032 ) and incidence rate (IRR:0.32, 95% 0.17-0.59, P < 0.001) of severe infections than BsAb.

of evaluated autoantibodes were significantly higher in Long-COVID compared to the 2 other groups (p higher number of patients with simultaneous detection of more than one autoantibody in Long-COVID group (p ARB1 and ARB2 correlated negatively CERAD Trail Marking A and B (R ≤ -0.26, p ≤ 0.043), while CHRM3 correlated positively with Chadler Fatigue Scale (R = 0.37, p = 0.0087).

patients receiving CLAG-M/sorafenib at RP2D (OS: hazard ratio,0.24 [95% confidence interval, 0.07-0.82]; P = .023; EFS: hazard ratio, 0.16 [95% confidence interval, 0.05-0.53]; P = .003). Benefit was limited to patients with intermediate-risk disease (univariate analysis: P = .01 for OS; P = .02 for EFS).

However, Vibrio parahaemolyticus infection poses a major challenge in ensuring the success of P. vannamei conducted to identify the interaction sites and binding affinity between several immune-related proteins of P. The P. vannamei-V. parahaemolyticus protein-protein interaction of Complex 1 (Ferritin-HrpE/YscL family simulation analysis, which revealed these complexes greatly contribute to the interactions between P.

, 53% had the extramedullary disease (EMD) at relapse, associated with dismal post-relapse outcome (P talquetamab, 64% and 32% for teclistamab, 30% and 0% for IMiDs/PIs/CD38, and 26% and 3% for others (P Duration of response, as well as median survival, was significantly improved with bispecific antibodies (P

On multivariable analysis, hypogammaglobulinemia (hazard ratio [HR], 6.06; P = .044) and diagnosis of an early respiratory viral infection (HR, 2.95; P = .048) were independent risk factors for late respiratory Nadeem , Adam S Sperling , Noopur Raje , Nikhil Munshi , Matthew Frigault , Sara Barmettler , Sarah P

Authors Bikash Chandra Jena, Daniel P Flaherty, Valerie P O'Brien, Val J Watts Tags Adenylyl Cyclase

obesity Date & Time Friday, November 3rd / 2:45 PM Abstract Coming Soon Authors and Affiliations Ryan P. Ayala 5, Owen P. McGuinness 5, Sheila Collins 1,5, Heidi E.

Kristina Sterner , Susanne Schinke , Nadja Käding , Jens Y Humrich , Otávio Cabral-Marques , Joana P

Authors Kirti V Sawant , Krishna Mohan Sepuru , Brigith Penaranda , Emily Lowry , Roberto P Garofalo

Authors R Mishra, S K Biswas, S Nandi, S Mahajan, K G Sai Balaji, V Gairola, D Poloju, S Gulzar, K P

Shafiei-Jahani, Shi Yan, Mohammad H Kazemi, Xin Li, Amitis Akbari, Kei Sakano, Yoshihiro Sakano, Benjamin P

gamma-AS1 , Interferon regulatory factor 1 , Interferon-gamma , Interleukin , Interleukin-1 receptor alpha P Sialic-acid-binding immunoglobulin-like lectin 8 , Signal transducer and activator of transcription , Substance P

Authors Nick D Bergkamp , Jeffrey R van Senten , Hendrik J Brink , Maarten P Bebelman , Jelle van den

Radomsky, Vasilis Panagiotopoulos, Robin du Preez, Michail Papadourakis, Konstantinos Tsianakas, Robert P

stability, warrant further evaluation of LP2's inhibitory potential of colorectal cancer. " Authors P

Rebecca Berdeaux , Dario A A Vignali , Ramiro Iglesias-Bartolome , Hannah Carter , Eytan Ruppin , Jill P

Feng, Rongfang Liu, Reno Brooks, Xuesong Wang, Willem Jespers, Marina Gorostiola González, Gerard J P

Authors Christopher T Schafer, Raymond F Pauszek 3rd, Martin Gustavsson, Tracy M Handel, David P Millar

</p> Taken together, in the acute setting of oxalate-induced nephropathy, the lack of the proton-activated

Authors Kathrine Lundø , Oksana Dmytriyeva , Louise Spøhr , Eliana Goncalves-Alves , Jiayi Yao , Laia P

Authors Peter J P Croucher , Maya Ridinger , Pamela S Becker , Tara L Lin , Sandra L Silberman , Eunice